✨ Free AI Report
Puma Biotechnology, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Puma Biotechnology, Inc.
Company Research

Puma Biotechnology, Inc.: Business Overview, Financials & Competitive Analysis

Puma Biotechnology, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Profitable, single-product biotech with strong NERLYNX commercial traction and pipeline hope from alisertib trials offering modest upside with manageable downside risk. Puma achieved strong profitability metrics with a 36.17% return on equity and 17.45% net margin in Q4 2025. The company guides full-year 2026 GAAP net income of $10M–$13M.

What is Puma Biotechnology, Inc.'s industry? Puma Biotechnology, Inc. (pumabiotechnology.com) operates in Biopharmaceutical - Oncology. AskCyborg classifies Puma Biotechnology, Inc. under Biopharmaceutical - Oncology in its company registry.

Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral versi...

7/ 10Strong

Cyborg Score thesis

Profitable, single-product biotech with strong NERLYNX commercial traction and pipeline hope from alisertib trials offering...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 12, 2026
AI-Verified Research
30+ Page Report

Get the Latest Puma Biotechnology, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Puma Biotechnology, Inc.

AskCyborg analysts argue the bull and bear cases for Puma Biotechnology, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Puma Biotechnology, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Puma Biotechnology, Inc. Overview

Pro stress-test →

Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib used to treat early-stage HER2-overexpressed/amplified breast cancer and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

Strategic Profile

Pro stress-test →

Puma demonstrated strong Q4 2025 commercial momentum with total revenue of $75.5M and product revenue of $59.9M, guiding 2026 net NERLYNX product revenue of $194M–$198M. The company is developing alisertib, a small molecule inhibitor of aurora kinase A for multiple cancer indications including breast cancer, small cell lung cancer, and head and neck cancer.

Competitive Landscape

Pro stress-test →

Puma competes in the HER2-positive breast cancer treatment market against established players like Roche/Genentech (Herceptin, Perjeta), AstraZeneca, and others. The company's NERLYNX addresses a specific indication for extended adjuvant treatment post-trastuzumab, differentiating from competitors. Alisertib pipeline development positions Puma to enter broader oncology markets if trials succeed.

Industry Context

Puma Biotechnology, Inc. operates in Biopharmaceutical - Oncology.

Key facts

Founded: 2010 · Headquarters: Los Angeles, US · Revenue: $212M · Market cap: $382.96M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Puma Biotechnology, Inc..

  • Puma targets $194–$198M in 2026 NERLYNX revenue with alisertib trials in breast and lung cancer progressing, including interim data expected in Q2 2026.
  • 75% of new NERLYNX patients started on reduced dose in Q4 2025 as the company implements dose escalation strategy to mitigate diarrhea side effects.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Puma presented at TD Cowen's 46th Annual Health Care Conference outlining 2026 guidance of $214M–$221M total revenue.
  • February 2026Q4 2025 earnings beat estimates with $0.26 EPS vs. $0.24 consensus and $75.5M revenue vs. $68.6M estimate.
  • +1 moreTrack every material event for Puma Biotechnology, Inc. as it happens. Explore monitoring →
Get alerted when Puma Biotechnology, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Herceptin / PerjetaHER2-targeted monoclonal antibodies for breast cancer→TykerbDual HER1/HER2 inhibitor for breast cancer→EnhertuHER2-directed antibody-drug conjugate for breast cancer→

Compare Puma Biotechnology, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Puma Biotechnology, Inc. operates in Biopharmaceutical - Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Oncology research →
NEW · MCP server

Ask your AI assistant about Puma Biotechnology, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Puma Biotechnology, Inc. and its top competitor on Cyborg Score”
“What did Puma Biotechnology, Inc. do this quarter?”
“Is Puma Biotechnology, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Puma Biotechnology, Inc. do?+
Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral versi...
What is Puma Biotechnology, Inc.'s Cyborg Score?+
Puma Biotechnology, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Puma Biotechnology, Inc.'s main competitors?+
Named competitors include Herceptin / Perjeta, Tykerb, Enhertu. The full competitive landscape is in the AskCyborg report.
How can I get the full Puma Biotechnology, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Puma Biotechnology, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Puma Biotechnology, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Syndax Pharmaceuticals, Inc.7Zai Lab Limited6Genenta Science4BioAtla, Inc.4Mersana Therapeutics, Inc.4Propanc Biopharma, Inc.3MacroGenics, Inc.